Amanote Research
Register
Sign In
Comparing Costs and Outcomes Between Coblation Technology and Mechanical Debridement in the Treatment of Knee Cartilage Lesions- A Cost-Effectiveness Analysis From a Us Payer Perspective
Value in Health
- United Kingdom
doi 10.1016/j.jval.2017.08.2017
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2017
Authors
A Adeyemi
L Nherera
P Trueman
G Delhougne
Publisher
Elsevier BV
Related search
Peritoneal Dialysis and In-Centre Haemodialysis: A Cost-Utility Analysis From a UK Payer Perspective
Applied Health Economics and Health Policy
Medicine
Health Policy
Economics
Econometrics
Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine for First-Line Treatment of Patients With Metastatic Pancreatic Cancer From the US Societal Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pmd79 - Cost-Effectiveness of Ultrasound-Guided Central Venous Catheterisation From the German Payer Perspective.
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Budget Impact Analysis of Balloon Dilation and Functional Endoscopic Surgery – A Us Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of Adding Carfilzomib to Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma From a US Perspective
Journal of Medical Economics
Health Policy
Pss29 - Secukinumab Versus Etanercept for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss35 - Secukinumab Versus Ustekinumab for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Future Costs and the Future of Cost-Effectiveness Analysis
Journal of Health Economics
Health Policy
Public Health
Occupational Health
Environmental
Pms42 - Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
